Session Title: Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery
Session Type: Abstract Submissions (ACR)
Background/Purpose: Mayo Hip questionnaire has previously been shown to have face, content and test-retest reliability. Our objective was to assess the validity and responsiveness of the Mayo Hip Questionnaire.
Methods: We used data from the Mayo Clinic Total Joint Registry to assess the validity of Mayo Hip questionnaire, by including patients who underwent primary total hip arthroplasty (THA) between 1993-2005 and responded to the baseline and 2-year post-primary THA Mayo Hip questionnaire. Mayo hip questionnaire assesses the domains of pain, function and mobility; reliability and construct validity has been previously established. It generates a total score clinical score ranging 0-80 (Excellent result is 72-80 points, good is 64-71 points, fair is 56-63 points, and poor is less than 55 points). Convergent/divergent validity was examined with the association of select demographics (age, gender, number of joints involved) at baseline with Mayo hip scores using linear regression analyses. Minimally Clinically Important Difference (MCID) and Really Important Difference (RID) were calculated corresponding to “somewhat better now” and “much better now”, respectively in response to patient-reported anchor at 2-years- Compared to your condition before the surgery, how would you rate your hip now? For discriminant ability, we calculated a) effect size by taking the change in respective score from baseline to 2-years and dividing the result by the standard deviation at baseline and b) the standardized response mean, defined as the mean change in the patient score with improvement at 2-years divided by the SD of the changed scores.
Results: For primary THA, there are 2,311 hips with both a baseline and a 2-year data. The sample consisted of 1,097 males (47.5%)and 1,214 females (52.5%). The mean age at surgery (SD) is 64 (13), median was 66 (range, 15-92). Age and gender were significantly associated Mayo Hip score at 2-years post-THA (p<0.001); and the number of joints involved was not associated (p=0.98). MCID was 24.8 and RID threshold was 37.1. Effect size at 2-years was large, 2.26 and the Standardized Response Mean was 2.25.
Conclusion: The Mayo Hip questionnaire is a valid and sensitive outcome measure for patients undergoing primary THA. This study provides further validation of this previously validated scale. Further validation in revision THA and in more diverse populations will provide more support to its validation as an outcome instrument.
J. A. Singh,
Savient, Takeda, Ardea, Regeneron, Allergan,
URL pharmaceuicals Novartis,
W. S. Harmsen,
DePuy, Stryker, Biomet and Zimmer.,
Zimmer, Orthosonic and Osteotech,
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-mayo-hip-questionnaire-validity-and-sensitivity-to-change/